Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic…
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with…
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia and Primary Myelofibrosis
Results From Ongoing Phase 1/2 Trial of SL-401 as Consolidation Therapy in…
Ongoing Phase 2 Clinical Trial of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Stage 1 and Stage 2 Results. EHA 2017.
Ongoing Phase 2 Clinical Trial of SL-401 in Patients with Blastic Plasmacytoid…
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors; Interim Results
Ongoing Phase 1 Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with…
Results From Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2016
Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with…
Phase 2 Trial of SL-701, a Novel Immunotherapy Comprised of Synthetic Short Peptides Against GBM Targets IL-13Rα2, EphA2, and Survivin, in Adults With Second-Line Recurrent GBM: Interim Results
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short…